Previous Article | Next Article 
Infection and Immunity, February 2000, p. 694-701, Vol. 68, No. 2
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Biochemical and Immunological Characterization of
MP65, a Major Mannoprotein Antigen of the Opportunistic Human Pathogen
Candida albicans
Maria J.
Gomez,1
Bruno
Maras,2
Alessandra
Barca,1
Roberto
La
Valle,1
Donatella
Barra,2 and
Antonio
Cassone1,*
Laboratory of Bacteriology and Medical
Mycology, Istituto Superiore di Sanità,1
and Department of Biochemical Sciences "A. Rossi Fanelli,"
University La Sapienza,2 Rome, Italy
Received 9 August 1999/Returned for modification 21 September
1999/Accepted 11 November 1999
 |
ABSTRACT |
In the search of the antigenic determinants of a 65-kDa
mannoprotein (MP65) of Candida albicans, tryptic fragments
of immunoaffinity-purified MP65 preparations were tested for their
ability to induce lymphoproliferation of human peripheral blood
mononuclear cells (PBMC). Five major peptides (T1 to T5) were shown to
induce a vigorous proliferation of PBMC from the majority of the eight
healthy human subjects tested. With the use of synthetic peptides,
critical amino acid sequences of the two most immunoactive (T1 and T2)
peptides were determined. Similar to what was found for the MP65
molecule, no PBMC multiplication was induced by the antigenic peptides
in cultures of naive cord blood cells. The amino acid sequence analysis
of tryptic and chymotryptic peptides of MP65 demonstrated a substantial homology with the deduced sequences of two cell wall proteins of
Saccharomyces cerevisiae, encoded by the genes
YRM305C and YGR279C. However, the antigenic
peptides were those showing the least similarity with the corresponding
regions of the above proteins. In particular, the
lymphoproliferation-inducing sequence of the T1 peptide scored only
20% identity with the homologous regions of S. cerevisiae
proteins. Besides disclosing the amino acid sequence of MP65, this
study provides an initial characterization of some of its antigenic
determinants, as well as of synthetic peptides of potential use to
detect specific immune responses against MP65, a major target of
anticandidal cell-mediated immunity in humans.
 |
INTRODUCTION |
Yeasts belonging to the genus
Candida are major fungal pathogens for the immunocompromised
host. Candida albicans is especially prevalent in subjects
infected by the human immunodeficiency virus with severe functional and
numerical deficits in CD4+ T lymphocytes, which are
critical components of cell-mediated immunity (CMI) (24).
Despite the increased awareness of the important role that CMI plays in
the defense against this fungal pathogen (reviewed in references
1 and 38), very few CMI antigen
targets for it have so far been identified. These include heat shock
proteins, enolase, and a number of as yet uncharacterized mannoproteins, some with adhesin function (6, 12, 15, 27, 29, 30,
40).
We have long been studying a 65-kDa mannoprotein (designated MP65)
which is present in both the structural and secretory mannoprotein material and which is recognized by T cells of peripheral blood of
practically all healthy individuals (quasiuniversal antigen) (20,
42-44). In mice immunized with whole fungal cells or MP65-rich mannoprotein extract (MP-F2) (44), a vigorous
lymphoproliferative response with a prevalent T-helper type 1 (Th1)
cytokine pattern was elicited in in vitro MP65-stimulated
lymphomonocyte cultures (31). In addition, the MP-F2 extract
was capable of inducing a moderate but significant degree of protection
against a challenge with a highly virulent C. albicans
strain in a model of murine disseminated candidiasis. This protection
was significantly increased by coadministration of interleukin-12
(IL-12) or by treatment with antibodies against IL-10 (32,
33).
Thus, MP65 contains Th1-inducing and potentially protective T-cell
epitopes, and its further biochemical and immunological characterization could be extremely useful for devising an
immunotherapeutic or vaccination strategy. With this aim in mind, we
have sequenced a large number of peptides obtained by enzymatic
digestion of a immunoaffinity-purified antigen. This sequencing
revealed that MP65 of C. albicans, while bearing substantial
homology to the products of a Saccharomyces cerevisiae gene
family encoding putative glucanase enzymes (10), also
possesses rather distinctive antigenic determinants in the N-terminal
region of the protein.
 |
MATERIALS AND METHODS |
Strains and culture conditions.
C. albicans BP,
serotype A, from the established stock collection of the Istituto
Superiore di Sanità, was used throughout this study. Its origin
and culture maintenance have been described elsewhere (44).
It was grown in Winge broth (0.2% glucose, 0.3% yeast extract; Difco)
or modified Lee's medium (28) buffered in 0.1 M phosphate
buffer, pH 6.5, as specified for single experiments.
Sera and MAbs.
7H6 is a mouse immunoglobulin G2b (IgG2b)
monoclonal antibody (MAb) specific for a peptide epitope of MP65. MAb
4H12 is a mouse IgG2a specific for the protein moiety of a 70-kDa
mannoprotein of C. albicans (20). Both MAbs were
prepared by fusion of the myeloma cell line X63-Ag8.653 with
splenocytes of mice immunized with a secreted mannoprotein material
from hyphal cell cultures of C. albicans and purified as
described in detail elsewhere (20). Polyclonal anti-MP65
antibodies were raised in 2-month-old, female BALB/c mice (Charles
River, Calco, Italy) by immunization with the purified MP65 coupled to
concanavalin A (ConA; Sigma Chemical, St. Louis, Mo.)-agarose beads, as
follows. Thirty micrograms (polysaccharide) of MP65 was incubated with
150 µg of ConA (12 mg of ConA per ml; Sigma) in 100 µl of buffer
containing 10 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2, and 1 mM MgCl2 (pH 7.5) for 1 h at 25°C; the mixture was
brought to 1 ml with double-distilled H2O and emulsified
into an equal volume of complete Freund's adjuvant. Two doses (200 µl) of this preparation were administered intraperitoneally to four
previously pristanized mice (0.5 ml of pristane given up to 2 weeks
before) at an 8-week interval. Five weeks later, mice received a third
dose of 8 µg of the soluble MP65 in incomplete Freund's adjuvant.
Ascites developed after the second or third injection, and ascites
fluid was collected and tested in an enzyme-linked immunosorbent assay
(20).
MP65 purification.
The MP65 was affinity purified from the
material spontaneously released from C. albicans mycelial
cultures, as previously reported (20). Briefly, the fungus
was grown in Lee's medium with 1 µg of tunicamycin/ml for 24 h
at 37°C. The culture supernatant was concentrated and dialyzed by
ultrafiltration (Diaflow Ultrafilter YM10; Amicon Corp., Danvers,
Mass.) and passed through two sequential affinity columns which were
prepared by covalently coupling MAb 7H6 or MAb 4H12 to protein
A-Sepharose CL4B (Pharmacia) with dimethylpimelimidate (Sigma). The
first (MAb 4H12) column was used to minimize nonspecific binding of
material from the mycelial secretion to the MP65-specific MAb 7H6
column. MP65 was eluted from the second (MAb 7H6) column with 100 mM
triethylamine, pH 11.5, neutralized with 2 M Tris, dialyzed against
double-distilled H2O, and kept at
20°C. The purified
antigen was substantially free from other mannoproteins or proteins, as
assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), silver staining, ConA detection, and immunoblotting with
MAbs or polyclonal antibodies directed against other components of the
mycelial secretion (16).
Total polysaccharide and protein compositions of MP65 were determined
by the phenol-sulfuric acid method (18) and the Bio-Rad (Hercules, Calif.) protein assay, respectively.
SDS-PAGE and Western blotting (immunoblotting).
Samples were
analyzed by SDS-PAGE with 5 to 15 or 5 to 20% gradient acrylamide slab
gels with a 3.5% acrylamide stacking gel (25, 27). After
electrophoresis, samples were either stained with the Bio-Rad silver
stain kit or transferred electrophoretically onto nitrocellulose (0.1- or 0.2-µm pore size) or polyvinylidene difluoride (PVDF) membranes
(Immobilon-P; Millipore Corp., Bedford, Mass.) for detection with ConA,
MAbs, or polyclonal antibodies or for amino acid sequencing, as
previously described (7, 20).
Enzyme treatments.
For limited proteolysis, 10 µg of
denatured MP65 (0.1% SDS, 100°C, 5 min) was resuspended in 50 mM
ammonium bicarbonate, pH 8.0, and digested with trypsin (Sigma Chemical
Co.) (enzyme/substrate ratio, 1:10 or 1:50) or chymotrypsin
(enzyme/substrate ratio, 1:100) for 1 h at 37°C. For extensive
proteolysis with trypsin or chymotrypsin, 400 µg of heat-denatured
(100°C, 5 min) MP65 in 50 mM Tris-HCl buffer, pH 8.0, was treated
with the corresponding enzyme (enzyme/substrate ratio, 1:10) for 2 to
5 h at 37°C. Cleavage with endoproteinase Asp-N (Boehringer
GmbH, Mannheim, Germany) (enzyme/substrate ratio, 1:50) was carried out
(under the same conditions) in the presence of 8% acetonitrile. The
extent of digestion was assessed by SDS-PAGE and silver staining.
High-performance liquid chromatography (HPLC) separation.
The peptide mixtures obtained following the enzymatic digestions with
trypsin (T peptides) or chymotrypsin (CH peptides) were purified using
the Beckman Gold chromatography system on a macroporous reversed-phase
column (Acquapore RP-300; 4.6 by 250 mm, 7 µm; Brownlee Labs, Foster
City, Calif.). Peptides were eluted with a linear gradient of 0 to 70%
acetonitrile in 0.2% (vol/vol) trifluoroacetic acid, at a flow rate of
1.0 ml/min. The elution was monitored using a diode array detector
(Beckman; model 168) at 220 and 280 nm. Peptides represented by peaks
were collected, lyophilized, and finally resuspended in 200 µl of
Dulbecco's phosphate-buffered saline (PBS; Oxoid).
Amino acid sequencing.
The peptides obtained by limited
proteolysis were separated in a 15 to 20% acrylamide gradient gel and
transferred onto PVDF membranes. After being stained with 0.1%
Coomassie blue in 50% methanol and destained with 50% methanol,
visualized bands were excised and subjected to automated Edman
degradation on a gas phase sequencer (model AB 476A; Perkin-Elmer,
Foster City, Calif.) (15). HPLC-purified peptides were
spotted (20 µl) in PVDF membranes before sequencing. In some cases,
the peptides were covalently linked to the membrane (Sequelon AA
membranes, Millipore) to avoid its detachment throughout sequencing
cycles (31).
Synthetic peptides.
Synthetic peptides were purchased from
Tana Laboratories, Houston, Tex.). They were provided as >80% pure
and were further assessed for purity by HPLC amino acid analysis and
sequencing, as described above. Because of their high hydrophobicity,
they were dissolved in 5% dimethyl-sulfoxide (DMSO; Sigma) at a
concentration of 1 mg/20 µl and then diluted to the desired
concentration in RPMI 1640 medium. DMSO controls demonstrated that the
concentrations used for peptide solubilization did not affect
peripheral blood mononuclear cell (PBMC) proliferation.
Lymphocyte proliferation assay.
Lymphoproliferation assays
were performed as previously reported (2, 3, 44). Briefly,
PBMC from venous blood samples of healthy human donors were isolated by
centrifugation on a density gradient (Lymphoprep; Nyegaard, Oslo,
Norway) and cultured at 37°C under a 5% CO2 atmosphere
in RPMI 1640 medium-5% pooled AB human serum (Sigma) in 96-microwell
trays (106 cells per ml, 200 µl per well) in the presence
of various doses of the stimulant and controls, as indicated in each
single experiment. Peptides isolated by HPLC were resuspended in
Dulbecco's PBS, heat inactivated (80°C, 10 min) as specified before,
filtered, and used at 1:100 or 1:1,000 (final dilution). In some
experiments, antigen-unresponsive PBMC from umbilical cord blood were
used as responder cells. Cell proliferation was measured on day 7 of the culture by [3H]thymidine incorporation and expressed
as counts per minute per 2 × 105 cells (mean ± standard deviation of triplicate wells) and by stimulation index (SI;
test counts per minute divided by control counts per minute for the
PBMC culture without stimulant). SI > 3 was considered to
indicate a positive lymphoproliferation.
 |
RESULTS |
MP65 purification.
The MP65 was purified from protein-enriched
secretory mannoprotein from hyphal cells of C. albicans by
double sequential immunoaffinity chromatography. To this end, two MAbs,
one of which (MAb 4H12) adsorbed an abundant 70-kDa molecule and other
irrelevant mannoproteins of the secretory material and the other of
which (MAb 7H6) bound specifically the MP65 constituent, were used. As
shown in Fig. 1, the purified antigen
intensely reacted with specific reagents and was substantially free
from other mannoproteins or proteins, as assessed by silver staining,
measurement of ConA reactivity, and immunoblotting with MAb 4H12
directed against the 70-kDa mannoprotein-rich material. This
purification procedure was reproduced with similar efficiencies for all
four batches of MP65 used throughout our experiments. The
immunoaffinity-purified MP65 did not contain Limulus
amoebocyte lysate-detectable lipopolysaccharide (data not shown).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 1.
Chemical and immunochemical detection of
immunoaffinity-purified MP65. (A) ConA stain; (B to D) immunoreactivity
with MAb 7H6 (B), anti-MP65 mouse serum (C), and MAb 4H12 (D); (E)
silver stain. Lanes 1, secretory mannoprotein material from
tunicamycin-treated mycelial cultures of C. albicans used as
starting material for the immunoaffinity purification of MP65, for
which 2 µg of polysaccharide material was reacted with ConA and 10 µg was reacted with each antibody preparation; lanes 2, 50 ng of
purified MP65 was reacted with ConA, 100 ng was reacted with
antibodies, and 1 µg was reacted with silver. Molecular mass markers
(left) are in kilodaltons.
|
|
MP65 protease digestion and PBMC proliferation.
To identify
enzymatic treatments useful to generate MP65 peptides with functional
antigenic determinants, several preparations of the purified molecule
were subjected to enzymatic digestion with trypsin or chymotrypsin or
Asp-N endoproteinase and tested in a lymphoproliferation assay. Only
the peptide mixture generated by trypsin cleavage had preserved the
capacity of inducing a strong proliferation of PBMC from
MP65-responsive donors in vitro (data not shown). Therefore, tryptic
digestions of four different batches of MP65 were carried out, and the
resulting main peptides obtained were separated by reversed-phase HPLC.
The chromatographic profiles obtained in the four digestions were
similar, but some minor differences in the number (from 40 to 45) or in
the height of the main peptide peaks were seen. Figure
2 is a representative chromatogram of a
trypsin digest of one of the four immunoaffinity-purified MP65 preparations.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
HPLC separation of MP65 peptides obtained by complete
proteolysis with trypsin. The chromatogram is one representative of
four independent preparations. Arrows, peptides analyzed for amino acid
sequence (T1 to T9); dashed line, gradient concentration.
|
|
PBMC from eight unrelated healthy blood donors were tested with all the
HPLC-separated peptides, five of which (T1 to T5, at a dilution of
1:100) were found to induce proliferation of PBMC from at least one of
the donors. At the above dilution, two peptides (T1 and T2) stimulated
cell proliferation in all (T1) or the majority (T2) of PBMC donors,
with proliferation indices falling in the same range as those
achievable with MP65 and the polyclonal stimulant IL-2 (data not shown;
see also below). No cell proliferation was induced by control buffers.
On this basis, all the subsequent experiments of PBMC stimulation by
antigenic MP65 fragments and synthetic peptides were carried out with
the peptides T1 and T2 (see below).
The antigenic nature of the peptide-induced lymphoproliferative
response, such as that previously shown for MP65 (20, 44), was confirmed by the inability of the relevant preparation to stimulate
lymphoproliferation in cultures of mitogen-responsive, naive
lymphocytes from the human umbilical cord blood (data not shown). Table
1 shows the actual lymphoproliferative
responses of all eight donors whose PBMC were stimulated in vitro with
peptides T1 and T2. Peptide T6 served as the negative control.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Lymphoproliferation induced by MP65 and some of the
internal peptides separated from MP65 by HPLC of human PBMC cultures
from adult healthy donors or umbilical cord blood
|
|
Amino acid sequences of antigenic and nonantigenic peptides.
The amino acid sequences of the MP65 peptides were determined following
total digestion with trypsin or chymotrypsin. In particular, the
complete amino acid sequence of peptide T1 was determined after a
further cleavage with chymotrypsin, HPLC separation, sequencing of the
resulting peptides, and comparison with the amino acid composition of
the whole, initial peptide from trypsin digestion. None of the main
peptides examined had overlapping amino acid sequences, indicating that
they were indeed distinct MP65 fragments (Table
2). The sequence of the T9 peptide
corresponded to the previously reported N-terminal sequence
(20).
For the amino acid homology search, the peptides above and other MP65
fragments obtained by partial or complete cleavage with trypsin or
chymotrypsin were sequenced and screened with database protein
sequences. Following limited digestion with trypsin or chymotrypsin,
several fragments ranging in apparent molecular mass from around 28 to
less than 14 kDa were obtained (Fig. 3). Only fragments of trypsin digestion with molecular masses of 28, 25, and 15 kDa (T28, T25, and T15, respectively) as well as one from
chymotrypsin digestion with a molecular mass of 26 kDa (CH26) were
detected after electrophoretic transfer to a PVDF membrane and
Coomassie blue staining. None of these large fragments reacted with
ConA in Western blotting showing that they were minimally, if at all,
glycosylated, and none was recognized by MAb 7H6 (Fig. 3). As shown in
Table 3, the amino acid sequences of the
28- and 25-kDa tryptic fragments were similar and overlapped with the
sequence of the 26-kDa chymotryptic fragment. Other overlappings with
peptides generated by extensive proteolysis were seen; in particular,
the 15- and 28-kDa tryptic fragments clearly contained the T1 and T2
peptides, respectively (compare with Table 2).

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis by SDS-PAGE and Western blotting of the MP65
fragments obtained by limited cleavage with trypsin (a) or chymotrypsin
(b). Samples of MP65 (lanes 1 of both panels) were digested at an
enzyme/substrate ratio of 1:50 or 1:10 for trypsin (a, lanes 2 and 3, respectively) or 1:100 for chymotrypsin (b, lanes 2). Protein fragments
were separated in 15 to 20% acrylamide gels and visualized with silver
stain (A) or with ConA (B) (both panels) or anti-MP65 mouse serum (a,
C) or MAb 7H6 (b, C) after electrophoretic transfer to PVDF membranes.
Peptide fragments analyzed for amino acid sequence were CH26, T28, T25,
and T15. Molecular mass markers (right) are in kilodaltons.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Amino acid sequences of major MP65 fragments from limited
trypsin or chymotrypsin digestion or complete chymotrypsin digestion
|
|
A search of protein databases revealed a high degree of similarity
between the sequences of most of the MP65 peptides and the deduced
amino acid sequences of two proteins encoded by the S. cerevisiae genes YRM305C and YGR279C. Figure
4 shows the sequences of these S. cerevisiae gene products aligned with the putative corresponding
peptides of Candida MP65. The previously reported N terminus
sequence of MP65 is also shown. Based on sequence comparison, the
homology between the sequences of the MP65 peptides and the deduced
amino acid sequences encoded by the S. cerevisiae genes is
particularly high (up to 70% identity) in several regions of the
C-terminal moiety of the protein. However, the identity score was much
lower in the MP65 antigenic peptides, in particular for the T1 peptide
(compare sequences of amino acids 195 to 217 of Fig. 4).

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 4.
Alignment of C. albicans MP65 sequenced
peptides (boldface) and the predicted amino acid sequences of S. cerevisiae YRM305C (sequence 1) and YGR279C (sequence
2) gene products as described by Cappellaro et al. (10).
Lowercase letters were used when the MP65 amino acids were different
from the corresponding amino acids of either of the S. cerevisiae proteins. The asterisk indicates the start of the
N-terminal sequence of the mature MP65 protein.
|
|
Identification of T1 and T2 as putatively immunodominant MP65
sequences.
Since all (for T1) or most (for T2) of the subjects
tested responded to the T1 and T2 peptides, we focused our attention on these two peptides as highly antigenic, putatively immunodominant determinants of MP65 (see above). To this end, the whole T1 and T2
peptides and two partially overlapping sequences (14 to 16 amino acids)
of each of the two peptides were synthesized by using the sequence
information derived from complete and incomplete MP65 enzymatic
digestion (Tables 2 and 3) and used to stimulate in vitro PBMC from
MP65- and natural T1- and T2-responsive donors. The whole T1 and T2
synthetic peptides were extremely hydrophobic and could hardly be
dissolved at sufficient concentrations in PBS to be tested in
lymphoproliferation assays. As shown in Table 4, the synthetic peptides possessing the
last six and four C terminus amino acids of T1 and T2 peptides,
respectively, induced lymphoproliferation in all four donors tested,
although by magnitudes that differed greatly, as exemplified by both
absolute counts per minute and proliferation indices. These data
confirm that the recognition of the natural T1 and T2 peptides by PBMC
was genuine and specific and did not depend upon contamination with other lymphoproliferation-inducing natural peptides with undefined amino acid sequences. They also indicate that the C terminus sequences ESLAEAVK and NVIR were critical components of T1 and T2 antigen recognition, respectively.
Biochemical properties of MP65, YRM305C, and YGR279C.
The two
S. cerevisiae gene products and MP65 of C. albicans share a number of biochemical properties. They have
acidic pI values and similar overall amino acid compositions, with high relative contents (>10% of the whole composition) of aspartic acid/asparagine, serine, glycine, alanine, and valine. The total content of hydroxy amino acids was particularly high (>20% of total
amino acids) for all three proteins (Table
5). In S. cerevisiae protein
sequences, around 50% of the hydroxy amino acids are located in the
first (N-terminal) portion of the molecule, being particularly concentrated between residues 106 and 135 (Fig. 4). This suggests that
most of the O glycosylation may occur in this area also in C. albicans MP65. One putative N glycosylation site was also
identified in both S. cerevisiae deduced amino acid
sequences, but no such a site was present in any of the MP65 sequenced
peptides.
View this table:
[in this window]
[in a new window]
|
TABLE 5.
Comparison between the deduced amino acid compositions of
the S. cerevisiae mature proteins encoded by
YRM305C and YGR279C and that of
C. albicans MP65a
|
|
 |
DISCUSSION |
In this paper, a 65-kDa mannoprotein (MP65), a major antigen
target of anti-Candida CMI, has been dissected into a number of PBMC-stimulatory peptide fragments. At least two peptides have been
found to contain major antigenic determinants of the fungus. They were
seen to belong to a protein closely homologous to S. cerevisiae cell wall mannoproteins, designated by Cappellaro et al. (10) Scw4p and Scw10p and apparently encoded by
the yeast genes YRM305C and YGR279C
(20).
To our knowledge, MP65 is the first cell wall mannoprotein antigen of
C. albicans that has been partially dissected into its antigenic determinants after molecular characterization and sequencing. There are several other mannoproteins of this fungus which approximate the molecular weight of the MP65 constituent, and some of them have
been, in part, characterized at a molecular level. In general, they
have usually been studied for adhesion to plastic or the cell surface
or as receptors for soluble factors of host immunity rather than as CMI
targets (4, 5, 8, 9, 19, 45, 46). A few of them have also
been shown to be recognized as antigens. For instance, the C3d-binding
protein (a doublet of 55 to 60 kDa and with a pI around 4) was
antigenically expressed and it induced in vitro proliferation of
splenocytes from Candida-infected mice (8).
However, no precise identification of its antigenic determinants has
been made, and the protein remains quite distinct from the MP65 antigen
of C. albicans. Lack of biochemical characterization and
sequence data for other MP-rich antigenic preparations of C. albicans precludes any sensible structural and functional
comparison with our antigenic constituent (16, 17, 35).
Besides the remarkable technical difficulties in purifying (and
sequencing) individual mannoproteins from polydispersed, highly glycosylated material, as previously discussed (11, 34), the paucity of data on the protein constituent of mannoproteins is also due
to the fact that most research has been focused on saccharide determinants of the antibody response for serotyping and diagnostic purposes (39, 41). Consequently, a wealth of knowledge has been accumulated on
- and
-linked oligomannosides involved as B-cell epitopes, one of which has recently been shown to induce antibody-mediated protective immunity (21, 22). In contrast, the protein moieties of most mannoproteins remain rather mysterious, despite previous indirect evidence that their epitopes may constitute the target of such responses as delayed type hypersensitivity in vivo,
ex vivo lymphoproliferation, and Th1 cytokine production (2, 3,
16, 17, 32), all critical elements of anti-Candida immunity (36, 38).
Amino acid sequence analysis of MP65 fragments obtained from partial or
complete trypsin and chymotrypsin digestion revealed a substantial
homology of this protein to products of a family of S. cerevisiae open reading frames (ORF), mostly YRM305C
and YGR279C, recently identified by Cappellaro et al.
(10) and shown to belong to a family of cell wall glucanases
or transglycosidases. Among the sequenced MP65 peptides, those having
the strongest homology to the deduced S. cerevisiae amino
acid sequences were present in the C-terminal half of the molecule. The
N-terminal amino acid sequences of fragments T28 and T25 and, mostly,
the T1 fragment from the complete trypsin digestion showed the lowest degree of sequence homology with the S. cerevisiae gene
products. All these sequences apparently belonged to the N-terminal
half of the molecule. The two S. cerevisiae gene products
show a high degree of potential O-glycosydic bonds, serine and
threonine accounting for more than 20% of all amino acids. A long
stretch of serine residues in positions 106 to 130 also characterizes
the products of the two S. cerevisiae ORF. This region
should be therefore considered as putatively involved in most of the
MP65 O glycosylation. This hypothesis is supported by the observation
that MP65 peptides obtained by limited proteolysis (T28, T25, T15, and
CH26), while matching the corresponding S. cerevisiae
regions (amino acid positions 146 and 144 of YRM305C and
YGR279C, respectively) did not react with ConA in Western
blotting (Fig. 3), nor did antigenic peptides T1 to T5 react with this
lectin (as indicated in Fig. 2).
Other close resemblances between MP65 and the Scw10p and Scw4p of
S. cerevisiae concern the nature of their cell walls and of
their secretory mannoproteins and their release from the cell wall by
reducing agents (10, 44). Although one site of potential N
glycosylation (NXS or NXT) is present in both Scw10p and Scw4p, no such
sites were identified in the putatively corresponding positions in any
of the sequenced MP65 peptides. Previous studies showed that
-mannosidase and
-elimination, but not endoglycosidase, treatments affected the molecular mass of MP65 (20, 45).
Moreover, the purified molecule was not reactive with any MAb
recognizing common
- or
-mannan epitopes of a large
variety of Candida mannoproteins (M. J. Gomez and A. Cassone, unpublished observations). It is possible that N glycosylation
sites reside in other nonsequenced MP65 regions or that the protein is
not N glycosylated, as happens for other cell wall mannoproteins
(23).
Since MP65 is particularly abundant in the secretory mannoprotein
material from the hyphal cells of C. albicans
(44), its apparent homology with enzymes of the glucan
metabolism would suggest a major function of it during mycelial growth,
when the level of
-glucanase activity is high and dramatic
rearrangements of cell wall structure and cell surface antigen
modulations occur (14). However, no direct data on the
biochemical function of MP65 are presently available.
A main purpose of the present study was the dissection of MP65 into its
main antigenic determinants recognized by human PBMC. A number of
tryptic or chymotryptic fragments were indeed separated by HPLC, their
amino acid sequences were largely determined, and their abilities to
induce PBMC proliferation in a number of subjects were tested. A more
extensive testing with a high number of subjects and with various exact
(molar) concentrations of each peptide could not be done as the amounts
of peptide recovered from HPLC were low and the amount of MP65 itself
achievable on a laboratory scale was not sufficiently high for complete
chemical characterization of its trypsin digests. Moreover, the methods
used could not guarantee that the antigenic peptides identified were
totally sequenced, so as to exactly define their concentrations.
Nonetheless, initial experiments with synthetic peptides provided
direct evidence that at least two peptides (T1 and T2) contained
genuine antigenic determinants and helped to more closely define the T1
and T2 regions representing or containing the epitope sequences.
Interestingly, upon alignment of their sequences with the corresponding
sequences of S. cerevisiae cell wall proteins, both peptides
appeared to be localized in that portion of the molecule showing the
least homology with the corresponding region of the yeast proteins. In
fact, the immunoactive T1b peptide showed 80% sequence diversity compared to the corresponding S. cerevisiae region, whereas
for the T2b peptide the diversity was >40%. The distinctiveness of what putatively contains major T-cell epitopes of MP65 might explain why mannoprotein extracts of S. cerevisiae, also containing
MP65-like molecules, are substantially devoid of lymphoproliferation
induction ability (A. Cassone, M. J. Gomex, and A. Torosantucci,
unpublished data). In addition, the Scw10p and Scw4p sequences did not
contain the lymphoproliferation-relevant epitope recognized by MAb 7H6 (20) that has recently been identified close to the
N-terminal end of MP65 (C. Bromuro, R. La Valle, and A. Cassone,
unpublished data).
It was previously shown that the MP65-containing MP-F2 fraction is
recognized by human PBMC as a classical antigen rather than as a
mitogen or a superantigen because its recognition requires antigen-presenting cells, is blocked by antibodies against class II
histocompatibility antigens, and does not occur in naive cord-blood lymphocytes (2, 3, 26, 45). Although more studies with T-cell lines or clones are required for a full definition of the antigenic properties of MP65 peptides, including their recognition by
T-cell epitopes, we have confirmed here that both T1 and T2 peptides
are unable to stimulate naive cord blood lymphocytes to proliferate,
thus possibly behaving as true antigens. A point of interest is also
the low level or absence of glycosylation of these peptides, as shown
by their inability to react with ConA. This suggests that the MP65
molecule is not uniformly glycosylated and that highly antigenic
determinants of the human anti-Candida response have been
selected among the least-glycosylated molecular regions of it. The
immunoactivity of the synthetic peptides T1b and T2b supports this interpretation.
As discussed elsewhere (11, 12), MP65 is recognized by
almost all healthy subjects that have so far been tested in our and
other laboratories (overall totaling several hundred subjects). The T1
and T2 peptides studied here also induced lymphoproliferation in the
great majority of the subjects examined, although the number of
subjects was rather small. A mixture of well-defined MP65 peptides or a
recombinant MP65 could therefore constitute a much more reliable reagent than those crude antigenic fractions used as recall antigens to
assess the CMI response under various conditions, including the loss
and recovery of CD4+ T-cell function in human
immunodeficiency virus-positive subjects under therapy (13,
37). Crude antigenic fractions are indeed difficult to
standardize and often produce unreliable results. The peptide sequences
described here along with the recognized homology with the S. cerevisiae cell wall mannoproteins (10) will also
facilitate the molecular cloning and the expression of a recombinant
protein, a necessary step for a full evaluation of the immunogenicity
and protective values of this immunodominant antigen of C. albicans.
 |
ACKNOWLEDGMENTS |
This work was supported by the National AIDS Project, Istituto
Superiore di Sanità, Contract no. 50B/B.
The authors are grateful to Anna Botzios and Francesca Girolamo for
help in the preparation of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Bacteriology and Medical Mycology, Istituto Superiore di Sanità,
Viale Regina Elena, 299, 00161 Rome, Italy. Phone: 39-06-49387113. Fax: 39-06-49387112. E-mail: cassone{at}iss.it.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Ashman, R. B., and J. M. Papadimitriou.
1995.
Production and function of cytokines in natural and acquired immunity to Candida albicans infection.
Microbiol. Rev.
59:664-672.
|
| 2.
|
Ausiello, C. M.,
G. C. Spagnoli,
M. Boccanera,
I. Casalinuovo,
F. Malavasi,
C. U. Casciani, and A. Cassone.
1986.
Proliferation of human peripheral blood mononuclear cells induced by Candida albicans and its cell wall fractions.
J. Med. Microbiol.
22:195-202[Abstract].
|
| 3.
|
Ausiello, C. M.,
F. Urbani,
S. Gessani,
G. C. Spagnoli,
M. J. Gomez, and A. Cassone.
1993.
Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans.
Infect. Immun.
61:4105-4111[Abstract/Free Full Text].
|
| 4.
|
Bendel, C. M.,
J. St. Sauver,
S. Carlson, and K. Hostetter.
1995.
Epithelial adhesion in yeast species: correlation with surface expression of the integrin analog.
J. Infect. Dis.
171:1660-1663[Medline].
|
| 5.
|
Bouchara, J. P.,
G. Tronchin,
V. Annaix,
R. Robert, and J. M. Senet.
1990.
Laminin receptors on Candida albicans germ tubes.
Infect. Immun.
58:48-54[Abstract/Free Full Text].
|
| 6.
|
Bromuro, C.,
R. La Valle,
S. Sandini,
F. Urbani,
C. M. Ausiello,
L. Morelli,
C. Fè d'Ostiani,
L. Romani, and A. Cassone.
1998.
A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis.
Infect. Immun.
66:2154-2162[Abstract/Free Full Text].
|
| 7.
|
Burnette, N.
1981.
"Western blotting": electrophoretic transfer of protein from dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.
Anal. Biochem.
112:195-203[CrossRef][Medline].
|
| 8.
|
Calderone, R.,
E. Enache,
T. Eskandri,
E. Wadsworth, and J. Sturtevant.
1997.
Adherence of Candida albicans to mammalian cells in vitro: nutritional influences, p. 73-83.
In
S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanism. Saikon Publishing Co., Ltd., Tokyo, Japan.
|
| 9.
|
Calderone, R. A.,
L. Linehan,
E. Wadsworth, and L. Sandberg.
1988.
Identification of C3d receptors on Candida albicans.
Infect. Immun.
56:252-258[Abstract/Free Full Text].
|
| 10.
|
Cappellaro, C.,
V. Marsa, and W. Tanner.
1998.
New potential cell wall glucanases of Saccharomyces cerevisiae and their involvement in mating.
J. Bacteriol.
180:5030-5037[Abstract/Free Full Text].
|
| 11.
|
Cassone, A.
1997.
Mannoproteins of Candida albicans in host-parasite relationship, p. 147-154.
In
S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanism. Saikon Publishing Co., Ltd., Tokyo, Japan.
|
| 12.
|
Cassone, A.,
F. De Bernardis,
C. M. Ausiello,
M. J. Gomez,
M. Boccanera,
R. La Valle, and A. Torosantucci.
1998.
Immunogenic and protective Candida albicans constituents.
Res. Immunol.
149:289-298[CrossRef][Medline].
|
| 13.
|
Cauda, R.,
E. Tacconelli,
M. Tumbarello,
G. Morace,
F. De Bernardis,
A. Torosantucci, and A. Cassone.
1999.
Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infections: a prospective case-control study.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
21:20-25.
|
| 14.
|
De Bernardis, F.,
A. Molinari,
M. Boccanera,
A. Stringaro,
R. Robert,
J. M. Senet,
G. Arancia, and A. Cassone.
1994.
Modulation of cell surface-associated mannoprotein antigen expression in experimental candidal vaginitis.
Infect. Immun.
62:509-519[Abstract/Free Full Text].
|
| 15.
|
Deepe, G. S., Jr.
1997.
Prospects for the development of fungal vaccines.
Clin. Microbiol. Rev.
10:585-596[Abstract].
|
| 16.
|
Domer, J. E.
1989.
Candida cell wall mannan: a polysaccharide with diverse immunologic properties.
Crit. Rev. Immunol.
17:33-51.
|
| 17.
|
Domer, J. E.,
S. Li,
Y. Wang, and S. Lee.
1997.
Immunoregulatory studies with Candida albicans mannan, p. 161-168.
In
S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanism. Saikon Publishing Co., Ltd., Tokyo, Japan.
|
| 18.
|
Dubois, M.,
K. A. Gilles,
J. K. Hamilton,
P. A. Rebers, and F. Smith.
1956.
Colorimetric method for determination of sugars and related substances.
Anal. Chem.
28:350-356[CrossRef].
|
| 19.
|
Gilmore, B. J.,
E. M. Retsinas,
J. S. Lorenz, and M. K. Hostetter.
1988.
A C3d receptor on Candida albicans: structures, function and correlates for pathogenicity.
J. Infect. Dis.
157:38-41[Medline].
|
| 20.
|
Gomez, M. J.,
A. Torosantucci,
S. Arancia,
B. Maras,
L. Parisi, and A. Cassone.
1996.
Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans.
Infect. Immun.
64:2577-2584[Abstract].
|
| 21.
|
Han, Y., and J. E. Cutler.
1995.
Antibody response that protects against disseminated candidiasis.
Infect. Immun.
63:2714-2719[Abstract].
|
| 22.
|
Han, Y.,
T. Kanbe,
R. Cherniak, and J. E. Cutler.
1997.
Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies.
Infect. Immun.
65:4100-4107[Abstract].
|
| 23.
|
Kapteyn, J. C.,
H. Van Den Ende, and F. M. Klis.
1999.
The contribution of cell wall proteins to the organization of the yeast cell wall.
Biochim. Biophys. Acta
1426:373-383[Medline].
|
| 24.
|
Klein, R. S.,
C. A. Harris,
C. B. Small,
B. Moll,
M. Lesser, and G. H. Friedland.
1984.
Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome.
N. Engl. J. Med.
311:354-358[Abstract].
|
| 25.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 26.
|
La Sala, A.,
F. Urbani,
A. Torosantucci,
A. Cassone, and C. M. Ausiello.
1996.
Mannoproteins from Candida albicans elicit a Th-type1 cytokine profile in human Candida specific long-term T cell cultures.
J. Biol. Regul. Homeost. Agents
10:8-12[Medline].
|
| 27.
|
La Valle, R.,
C. Bromuro,
L. Ranucci,
H. M. Muller,
A. Crisanti, and A. Cassone.
1995.
Molecular cloning and expression of 70kDa heat shock protein of Candida albicans.
Infect. Immun.
63:4039-4045[Abstract].
|
| 28.
|
Lee, K. L.,
H. R. Buckley, and C. C. Campbell.
1975.
An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida albicans.
Sabouraudia
13:148-153[Medline].
|
| 29.
|
Mathews, R., and J. Burnie.
1992.
The role of hsp90 in fungal infection.
Immunol. Today
13:345-348[CrossRef][Medline].
|
| 30.
|
Mathews, R.,
D. Smith,
J. Midgley,
J. Burnie,
I. Clark,
M. Conolly, and B. Gazzard.
1988.
Candida and AIDS: evidence for protective antibody.
Lancet
ii:263-265.
|
| 31.
|
Matsudaira, P.
1990.
Limited N-terminal sequence analysis.
Methods Enzymol.
182:602-613[Medline].
|
| 32.
|
Mencacci, A.,
A. Torosantucci,
R. Spaccapelo,
L. Romani,
F. Bistoni, and A. Cassone.
1994.
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.
Infect. Immun.
62:5353-5360[Abstract/Free Full Text].
|
| 33.
|
Mencacci, A.,
R. Spaccapelo,
G. Del Sero,
K. H. Essle,
A. Cassone,
F. Bistoni, and L. Romani.
1996.
CD4+ T-helper cell responses in mice with low-level Candida albicans infection.
Infect. Immun.
64:4907-4914[Abstract].
|
| 34.
|
Nelson, R. D.,
N. Shibata,
P. R. Podzorski, and M. J. Herror.
1991.
Candida mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action.
Clin. Microbiol. Rev.
4:1-19[Abstract/Free Full Text].
|
| 35.
|
Nelson, R. D.
1997.
Effects of Candida albicans mannans and mannan catabolites on human cell-mediated immune function in vitro, p. 169-173.
In
S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanism. Saikon Publishing Co., Ltd., Tokyo, Japan.
|
| 36.
|
Puccetti, P.,
L. Romani, and F. Bistoni.
1995.
A TH-1-TH-2-like switch in candidiasis: new perspectives for therapy.
Trends Microbiol.
3:237-240[CrossRef][Medline].
|
| 37.
|
Quinti, I.,
C. Palma,
B. C. Guerra,
M. J. Gomez,
A. Torosantucci, and A. Cassone.
1991.
Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected subjects.
Clin. Exp. Immunol.
85:485-492[Medline].
|
| 38.
|
Romani, L., and D. H. Howard.
1995.
Mechanisms of resistance to fungal infection.
Curr. Opin. Immunol.
7:517-523[CrossRef][Medline].
|
| 39.
|
Shibata, N.,
M. Arai,
E. Haga,
T. Kikuchi,
M. Najima,
T. Satoh,
H. Kobayashi, and S. Suzuki.
1992.
Structural identification of an epitope of antigenic factor 5 in mannan of Candida albicans.
Infect. Immun.
60:4100-4110[Abstract/Free Full Text].
|
| 40.
|
Sundstrom, P.,
J. Jensen, and E. Balish.
1994.
Humoral and cellular immune response to enolase after alimentary tract colonization or intravenous immunization with Candida albicans.
J. Infect. Dis.
170:390-395[Medline].
|
| 41.
|
Suzuki, S.
1997.
Structural investigation of mannans of medically relevant Candida species. Determination of chemical structures of antigenic factors 1, 4, 5, 6, 9 and 13b, p. 1-15.
In
S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanism. Saikon Publishing Co., Ltd., Tokyo, Japan.
|
| 42.
|
Torosantucci, A.,
C. Palma,
M. Boccanera,
C. M. Ausiello,
G. C. Spagnoli, and A. Cassone.
1990.
Lymphoproliferation and cytotoxic responses of human peripheral blood mononuclear cells to mannoprotein constituents of Candida albicans.
J. Gen. Microbiol.
136:664-672.
|
| 43.
|
Torosantucci, A.,
M. J. Gomez,
C. Bromuro,
J. Casalinuovo, and A. Cassone.
1991.
Biochemical and antigenic characterization of mannoprotein constituents released from yeast and mycelial form of Candida albicans.
J. Med. Vet. Mycol.
29:361-372[Medline].
|
| 44.
|
Torosantucci, A.,
C. Bromuro,
M. J. Gomez,
C. M. Ausiello,
F. Urbani, and A. Cassone.
1993.
Identification of a 65kDa mannoprotein as a main target of human cell-mediated immune response to Candida albicans.
J. Infect. Dis.
168:427-435[Medline].
|
| 45.
|
Tronchin, G.,
J. P. Bouchara,
V. Annaix,
R. Robert, and J. M. Senet.
1991.
Fungal cell adhesion molecules in Candida albicans.
Eur. J. Epidemiol.
7:23-33[Medline].
|
| 46.
|
Yu, L.,
K. K. Lee,
K. Ens,
P. C. Doig,
M. R. Carpenter,
W. Staddon,
R. S. Hodges,
W. Paranchych, and R. Irvin.
1994.
Partial characterization of a Candida albicans fimbrial adhesin.
Infect. Immun.
62:2834-2842[Abstract/Free Full Text].
|
Infection and Immunity, February 2000, p. 694-701, Vol. 68, No. 2
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pietrella, D., Lupo, P., Rachini, A., Sandini, S., Ciervo, A., Perito, S., Bistoni, F., Vecchiarelli, A.
(2008). A Candida albicans Mannoprotein Deprived of Its Mannan Moiety Is Efficiently Taken Up and Processed by Human Dendritic Cells and Induces T-Cell Activation without Stimulating Proinflammatory Cytokine Production. Infect. Immun.
76: 4359-4367
[Abstract]
[Full Text]
-
Nisini, R., Torosantucci, A., Romagnoli, G., Chiani, P., Donati, S., Gagliardi, M. C., Teloni, R., Sargentini, V., Mariotti, S., Iorio, E., Cassone, A.
(2007). {beta}-Glucan of Candida albicans cell wall causes the subversion of human monocyte differentiation into dendritic cells. J. Leukoc. Biol.
82: 1136-1142
[Abstract]
[Full Text]
-
Pietrella, D., Corbucci, C., Perito, S., Bistoni, G., Vecchiarelli, A.
(2005). Mannoproteins from Cryptococcus neoformans Promote Dendritic Cell Maturation and Activation. Infect. Immun.
73: 820-827
[Abstract]
[Full Text]
-
Pietrella, D., Mazzolla, R., Lupo, P., Pitzurra, L., Gomez, M. J., Cherniak, R., Vecchiarelli, A.
(2002). Mannoprotein from Cryptococcus neoformans Promotes T-Helper Type 1 Anticandidal Responses in Mice. Infect. Immun.
70: 6621-6627
[Abstract]
[Full Text]
-
Nisini, R., Romagnoli, G., Gomez, M. J., La Valle, R., Torosantucci, A., Mariotti, S., Teloni, R., Cassone, A.
(2001). Antigenic Properties and Processing Requirements of 65-Kilodalton Mannoprotein, a Major Antigen Target of Anti-Candida Human T-Cell Response, as Disclosed by Specific Human T-Cell Clones. Infect. Immun.
69: 3728-3736
[Abstract]
[Full Text]
-
La Valle, R., Sandini, S., Gomez, M. J., Mondello, F., Romagnoli, G., Nisini, R., Cassone, A.
(2000). Generation of a Recombinant 65-Kilodalton Mannoprotein, a Major Antigen Target of Cell-Mediated Immune Response to Candida albicans. Infect. Immun.
68: 6777-6784
[Abstract]
[Full Text]